H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy Rating

H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated (NASDAQ:CORT), reflecting a significant upside potential from its current trading level of $69.51 per share.

H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)'s $145 Price Target, Maintains Buy Rating

A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.

The reaffirmation followed Corcept Therapeutics Incorporated (NASDAQ:CORT)’s detailed presentation on its Phase 3 ROSELLA trial at the ASCO 2025 Annual Meeting.

The study is evaluating the efficacy of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Corcept Therapeutics Incorporated (NASDAQ:CORT) said the trial met its primary endpoint of improved progression-free survival, with patients experiencing a 30% reduction in the risk of disease progression, compared to those receiving nab-paclitaxel monotherapy.

H.C. Wainwright analysts noted the significance of these findings and decided to maintain their price target and rating for the stock.

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage company engaged in the discovery and development of treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol.

While we acknowledge the potential of CORT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CORT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now.

Disclosure: None.